most of the patients remain undiagnosed until they develop severe liver damage or submitted for serological screening. 3 About 184 million people worldwide are HCV-infected, 4 and early diagnosis and treatment allow virological cure in most of the cases. 5 Because HCV infection is usually asymptomatic, with insidious evolution and epidemic, 6 the screening for this infection can be considered strongly recommended for individuals who have some risk factors, who is blood donor or pregnant. 7, 8 The laboratory diagnosis of HCV infection has two steps 1,9 :
1. Blood samples are tested by screening methods which should have high sensitivity, usually immunological assays such as enzyme-linked immunosorbent assay, lateral immunoflow assay, dot blot Assay, and chemiluminescent assays.
2.
Prescreened positive samples are retested using a highly specific test such as nucleic acid tests (NAT) to detect viral RNA which confirms persistent viremia.
The confirmation is important due to the fact that immunological tests can present false positive (or undetermined) results. In addition, infected patients do not develop chronic infection; however, their serological status remains positive during lifetime. Besides NAT to detect viral RNA, viral load and genotyping are also important. 5, 10 There are 7 genotypes known, and one specific genotype can present more morbidity than another.
ELISA and related assays are the most widely immunological methods used for screening of suspected HCV cases. 11, 12 To allow screening in large-scale, recombinant antigens were developed, but during many years, the diagnostic industries had the patent rights to antigen production. 13 However, due to many patent rights have been expired (over 1990s) and with the advance and dissemination of the biotechnological techniques, several types of HCV antigens could be produced. 14, 15 The most important antigens for HCV antibody testing are Core, NS3, NS4, and NS5, 16 and in ideal conditions, a combination of these antigens should compose the diagnostic kit. The design, production, and purification of each antigen request time and lead to high cost besides different processes must be controlled.
The combination of different proteins together in a recombinant chimerical protein, which is expressed in a unique vector, have been considered a viable method to reduce the time and charge of the processes. In this system, the desired antigens are produced in a unique multiepitope protein, which should be similarly recognized by patient's antibodies compared to antigens separately. Therefore, the profile of reactivity must be warranted to avoid false positive or false negative results naturally with disastrous consequences to the patients. Thus, the laboratory validation of a new antigen has crucial importance prior to its use in diagnostics kits.
This study was aimed to evaluate the performance and to validate of a previously described recombinant multiepitope HCV antigen in three 3rd Generation diagnostic assay systems (ELISA, Western blot and dot blot) to detect anti-HCV IgG antibodies in human serum in a Brazilian cohort. 
| MATERIAL S AND ME THODS

| Serum panel
| Cloning and protein expression
An Escherichia coli codon optimized HCV synthetic gene containing Core 1b, Core 3g, NS3, NS4 I, NS4 II, and NS 5 HCV genes separated by a flexible linker (Gly-Ser-Gly-Ser-Gly), previously described in shaker which was set up for 120 rpm for protein expression.
| Protein purification
Cells of the two E. coli strains were pelleted by centrifugation 
| SDS-polyacrylamide gel electrophoresis
Briefly, proteins after purification from Arctic Express and BL21
were electrophoresed in vertical polyacrylamide gel (12.5%) using
Laemeli buffer containing SDS. Prestained protein weight marker (Fermentas, Pittsburgh, PA, USA) was used to estimate protein molecular weights. The gel was fixed, stained with comassie blue solution, and then destained.
| Immunoblot assay
Protein eluates, after electrophoresis in SDS-PAGE, were electron transferred from gel to nitrocellulose membranes. After confirmation of transference, the membranes containing the antigens were 
| Dot blot assay
Briefly, nitrocellulose membranes squares (approximately 1 cm 3 )
were coated with HCV antigen and then blocked with 2% bovine serum albumin (BSA). The coated membranes were incubated with patient′s serum diluted 1:1000 in PBS/BSA for 30 minutes at 37°C
and then washed. The membranes were incubated with anti-IgG horseradish-conjugated for 30 minutes at 37°C and washed.
The reactions were revealed with 3,3′-diaminobenzidine/hydrogen peroxide solution for 5 minutes at room temperature. The "dots"
were evaluated visually comparing the intensity of the staining. 
| Ethical concerns
| Statistical and data analysis
| Definitions
Sample was considered to be "positive" by ELISA if the SCI was ≥1.1 and "negative" if the SCI was ≤0.9. Sample with SCI between 1.1 and 0.9 was defined as "indeterminate." Interpretations of immunoblot and dot blot assays were performed visually.
| RE SULTS
| SDS-polyacrylamide gel electrophoresis
Arctic Express and BL21 expressed a 27 kDa protein compatible with the theoretical weight of the proposed recombinant multiepitope HCV antigen. However, BL21 presented better yield and purity than Arctic Express (Figure 1 ). The antigen purified from BL21 presented better yield, and therefore the following steps of this study were performed using only antigen purified from this expression vector.
| Immunoblot assay
The positive HCV samples (n = 20) were strongly reactive against antigen on the membranes, and the resulting bands were compatible with a 27 kDa protein (Figure 2 ). These results were 100% concordant with ELISA. The negative samples (n = 20) presented no bands in the Western blot assay.
| ELISA
The sample power analysis of the sampling resulted = 0.98 (1 − β) 
| Dot blot
The samples (20 positives and 20 negatives) tested by dots blot resulted in 100% of concordance with ELISA and Western blot. The best dilution of serum was 1:1000, and at this point, the "dots" staining presented strong discrimination between negative and positive samples ( Figure 6 ). Unspecific reactions were observed in serum dilution of <1:500.
| D ISCUSS I ON
The hepatitis C virus has a significant impact in the public health, and the diagnosis of HCV infection depends on screening methods followed by confirmatory techniques and clinical evaluation to set up the strategies for therapy. 5, 10 The ELISA and related methods are eligible due to lower cost and testing protocol facilities.
11,12
The capacity of a health system to early diagnose and, consequently, to treat the infected patients depends on the availability of kits. 7, 8 Most countries of Latin America as well as other developing and less-developing countries cannot produce their own diagnostic kits and import it from other countries. The capacity to produce the kit is closely related to the capacity to produce antigens. Thus, the know-how for production of a multiepitope antigen with a lower cost of production is desired.
In this study, we have optimized the expression and purification of a multiepitope HCV antigen previously proposed 14 with the aim to be used in diagnostic kits. The performance of this antigen was tested in three different immunological systems using a panel of samples which consisted of positive and negative sera previously tested for HCV antibodies. Different HCV genotyped sera and sera negative for HCV but positive for other infectious agents were also tested.
Samples (n = 461) presented results in agreement with the expected results, that is, samples from panel which were considered positive in previous tests were positive in three methods (ELISA, immunoblot assay and dot blot assay), and samples from panel which were considered negative in previous tests were negative.
No false positive neither false negative result was found, and no tests. 18, 19 Besides, no interference was observed among tested samples at least for syphilis, HIV, and hepatitis B.
Despite the fact that false positive or undetermined results can occur in the laboratory practice, the immunological tests are useful due to lower cost and simplicity to be performed. In screening tests, the higher sensibility is preferred instead of high specificity to minimize false negative results and the individuals screened as "positive"
are included in a list for confirmatory tests. Dot blot assay was simple to be performed, and it required no apparatus for interpretation of the results.
Previously studies 14, 20 have reported similar results concerning design of synthetic gene, protein expression, and purification. Dipti et al 14 have demonstrated that epitopes were well displayed using mouse antisera. Moreover, human sera panels (Boston Biomedical, USA) were tested by ELISA and samples were also tested by lateral flow assay, although the authors presented limited information about the sample features, number of sample tested as well as details of data analysis. However, the authors related specificity value of 100%, with a sensitivity value of 99.8%, and 100% of correlation with commercial kits.
Galdino et al 20 reported similar study that was tested 17 human positive (different genotypes) and 10 human negative sera samples In conclusion, the HCV multiepitope protein used in this study is a lower cost compared to individual production of each antigen separately. The antigen presented proper sensitivity and specificity as demonstrated in human sera and recognized all different virus genotypes. The proposed antigen is suitable to design kits, and we draw attention to dot blot assay which could be useful for laboratories that test small number of samples or those who do not have an ELISA reader.
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